Leo Pharma consolidates global commercial organization, reducing overall unit count

In an attempt to streamline and build a more competitive organization, the Danish dermatology firm has merged a number of international commercial divisions.
Leo Pharma's head of R&D, Jörg Möller, has reduced Leo Pharma's R&D division in the past as part overall streamlining efforts, which have now also impacted the firm's commercial units | Photo: MAGNUS MØLLER
Leo Pharma's head of R&D, Jörg Möller, has reduced Leo Pharma's R&D division in the past as part overall streamlining efforts, which have now also impacted the firm's commercial units | Photo: MAGNUS MØLLER
by ulrich quistgaard, translated by daniel pedersen

After holding meetings around the world, Leo Pharma can now announce that a number of the firm’s international sales units have been consolidated, the firm reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading